The 2008 World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues introduced a new category for myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Many of these cases present as a myeloproliferative neoplasm, usually with eosinophilia. However, neoplasms associated with rearrangement of PDGFRA can present as acute...

a-Interferon induces hematological and cytogenetic remissions in some individuals with newly diagnosed Philadelphia-positive chronic myelogenous leukemia. However, interferon-resistant disease occurs in a con sistent patient subset (primary resistance) and develops during therapy in additional patients (secondary resistance). Several o-interferon-inducible genes have been characterized. In inte...

alpha-Interferon induces hematological and cytogenetic remissions in some individuals with newly diagnosed Philadelphia-positive chronic myelogenous leukemia. However, interferon-resistant disease occurs in a consistent patient subset (primary resistance) and develops during therapy in additional patients (secondary resistance). Several alpha-interferon-inducible genes have been characterized. ...

BACKGROUND In this report, the isorhamnetin 3-o-robinobioside and its original extract, the ethyl acetate extract, from Nitraria retusa leaves, were evaluated for their ability to induce antioxidant and antigenotoxic effects in human chronic myelogenous leukemia cell line. METHODS Nitraria retusa products properties were carried out by firstly evaluating their effects against lipid peroxidati...

A recently developed liquid culture technique was used to determine the proliferative and maturational character istics of leukemia cells from 7 patients with chronic myelogenous leukemia (CML). Marrow and blood leukocytes were cultured in an in vitro diffusion chamber for up to 45 days. Proliferation was assessed by viable cell counts and thymidine-3H-labeling indices. Maturation was determined

T-cell blast crisis in chronic myelogenous leukemia is rare. We examined three patients (ages 35 to 72 years) in whom T-cell blast crisis developed 11 to 36 months (mean, 25 months) after diagnosis of chronic myelogenous leukemia and who died 4 to 12 months (mean, 7 months) thereafter. Two patients had diffuse lymphadenopathy, and the third had marked lymphocytosis (white blood cell count 217,0...

Blood, Vol. 50, No. 1 (July), 1977 115 The specificity of an antiserum (titer 1:500) raised in a monkey against K-562 undifferentiated cells with the Philadelphia chromosome (Ph’) was determined. Antibody-dependent, complement-mediated cytotoxicity was demonstrated for both bone marrow cells and peripheral leukocytes from patients with myelogenous and lymphatic leukemias, but not for mature nor...

A recently developed liquid culture technique was used to determine the proliferative and maturational character istics of leukemia cells from 7 patients with chronic myelogenous leukemia (CML). Marrow and blood leukocytes were cultured in an in vitro diffusion chamber for up to 45 days. Proliferation was assessed by viable cell counts and thymidine-3H-labeling indices. Maturation was determined

abstract the antineoplastic activities of alcoholic and aqueous extracts of the roots, stems and leaves of isatis campylocarpa an endemic species of the brassicaceae family from iran, investigated on the growth of jurkat as an acute lymphocytic leukemia cell line, k562 as a chronic myelogenous leukemia cell line and fen as a bladder cancer cell line using colorimetric assay. results showed that...